Danaher Corporation $DHR Shares Acquired by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab boosted its position in Danaher Corporation (NYSE:DHR) by 10.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 241,879 shares of the conglomerate’s stock after purchasing an additional 22,967 shares during the period. Danaher comprises approximately 0.9% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 27th largest position. Danica Pension Livsforsikringsaktieselskab’s holdings in Danaher were worth $45,860,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Enterprise Financial Services Corp lifted its holdings in shares of Danaher by 1.4% in the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock valued at $737,000 after buying an additional 46 shares during the period. Kennebec Savings Bank grew its holdings in Danaher by 1.4% during the fourth quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock worth $766,000 after acquiring an additional 46 shares during the period. Revolve Wealth Partners LLC raised its position in Danaher by 2.6% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock worth $428,000 after acquiring an additional 47 shares in the last quarter. High Note Wealth LLC raised its position in Danaher by 19.2% in the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock worth $67,000 after acquiring an additional 47 shares in the last quarter. Finally, First Command Advisory Services Inc. lifted its holdings in Danaher by 4.4% in the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock valued at $253,000 after acquiring an additional 47 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $179.01 on Wednesday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The stock has a market cap of $126.70 billion, a P/E ratio of 34.62, a PEG ratio of 2.48 and a beta of 0.79. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $184.22 and a two-hundred day moving average of $197.69.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.84 by $0.10. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.11 billion. During the same period in the prior year, the business earned $0.77 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, research analysts predict that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s payout ratio is 30.95%.

Analysts Set New Price Targets

Several brokerages have commented on DHR. Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Barclays reduced their price objective on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Wells Fargo & Company lowered their target price on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 22nd. TD Cowen reduced their price target on shares of Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, The Goldman Sachs Group lowered their price target on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $231.64.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise
• Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance
• Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.